Literature DB >> 31505704

The Spectrum of Genetic Defects in Congenital Adrenal Hyperplasia in the Population of Cyprus: A Retrospective Analysis.

Vassos Neocleous1,2, Pavlos Fanis1,2, Meropi Toumba1,3, Charilaos Stylianou4, Michalis Picolos5, Elena Andreou6, Andreas Kyriakou7, Michalis Iasonides8, Stella Nicolaou4, Tassos C Kyriakides9, George A Tanteles2,10, Nicos Skordis1,11,12, Leonidas A Phylactou1,2.   

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is caused by mutations in the CYP21A2 gene. The study refers to CAH patients of Greek-Cypriot ancestry between years 2007 and 2018. One hundred and twenty patients with various degrees of CAH were categorized and genotyped. The patients were categorized in 4 mutation groups based on their clinical and biochemical findings. The majority of patients (85.0%) belonged to the non-classic (NC)-CAH form and the disorder was more often diagnosed in females (71.7%). The most severe classic salt-wasting (SW) form was identified in 11 neonates (9.2%). Seven (5.8%) children were also identified with the simple virilizing (SV) form and a median presentation age of 5 years [interquartile range (IQR) 3.2-6.5]. In the 240 nonrelated alleles, the most frequent mutation was p.Val281Leu (60.0%) followed by c.655 A/C>G (IVS2-13A/C>G) (8.8%), p.Pro453Ser (5.8%), DelEx1-3 (4.6%), p.Val304Met (4.6%), and p.Gln318stop (4.2%). Other less frequent mutations including rare deletions were also identified. Following our recent report that the true carrier frequency of CYP21A2 in Greek-Cypriots is 1:10, this study reports that the CAH prevalence is predicted around 1.7 cases per 10 000 people. Therefore, the up-to-date 120 CAH patients identified by our group make only the 6.9% of the ones estimated (approximately 1750) to exist in the Greek Cypriot population. The compiled data from a coherent population such as the Greek-Cypriot could be valuable for the antenatal diagnosis, management and genetic counselling of the existing and prospect families with CAH. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31505704     DOI: 10.1055/a-0957-3297

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene.

Authors:  Pavlos Fanis; Nicos Skordis; Leonidas A Phylactou; Vassos Neocleous
Journal:  Hormones (Athens)       Date:  2022-10-20       Impact factor: 3.419

2.  Cardiometabolic Health in Adolescents and Young Adults with Congenital Adrenal Hyperplasia.

Authors:  Ruta Navardauskaite; Kristina Semeniene; Marius Sukys; Agne Pridotkaite; Aurika Vanckaviciene; Birute Zilaitiene; Rasa Verkauskiene
Journal:  Medicina (Kaunas)       Date:  2022-03-30       Impact factor: 2.948

3.  Molecular analysis and genotype-phenotype correlations in patients with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency from southern Poland - experience of a clinical center.

Authors:  Anna Kurzyńska; Anna Skalniak; Kim Franson; Viola Bistika; Alicja Hubalewska-Dydejczyk; Elwira Przybylik-Mazurek
Journal:  Hormones (Athens)       Date:  2022-01-26       Impact factor: 3.419

Review 4.  Polycystic ovarian syndrome in adolescents: From diagnostic criteria to therapeutic management.

Authors:  Nicolas C Nicolaides; Andreas Matheou; Florentia Vlachou; Vassos Neocleous; Nicos Skordis
Journal:  Acta Biomed       Date:  2020-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.